Quantcast
Home / DC News / Divided FDA panel urges more Avandia warnings, restrictions

Divided FDA panel urges more Avandia warnings, restrictions

Large group of members votes to pull drug from market entirely

WASHINGTON - In a fractured vote Wednesday, a significant number of members of an advisory committee for the Food and Drug Administration voted in favor of removing the controversial diabetes drug Avandia from the market in light of a reported increased risk of heart attack and other health problems.


Lawyers USA has ceased publication. If you have purchased a research pass or still have additional time on your current Digital Subscription, you may access locked stories by logging in:







Scroll To Top